Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
Andrew N Phillips, Loveleen Bansi-Matharu, Francois Venter, Diane Havlir, Anton Pozniak, Daniel R Kuritzkes, Annemarie Wensing, Jens D Lundgren, Deenan Pillay, John Mellors, Valentina Cambiano, Andreas Jahn, Tsitsi Apollo, Owen Mugurungi, David Ripin, Juliana Da Silva, Elliot Raizes, Nathan Ford, George K Siberry, Ravindra K GuptaRuanne Barnabas, Paul Revill, Jennifer Cohn, Alexandra Calmy, Silvia Bertagnolio
Dive into the research topics of 'Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines'. Together they form a unique fingerprint.